Evaxion reports EVX-01 induces strong immune responses in phase 2 melanoma trial

Bitget2026/11/06 16:00

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Evaxion announced new Phase 2 data showing strong immune responses to personalized cancer vaccine EVX-01 in patients with advanced melanoma.
Findings supported its AI platform’s ability to select vaccine targets likely to generate strong immune responses.
Results will be presented November 6-7, 2026, at the Society for Immunotherapy of Cancer annual meeting in Phoenix.
Previously presented three-year follow-up data showed sustained immune and clinical responses.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611061100OMX_____CNEWS_EN_GNW1001302254_en) on November 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Evaxion reports EVX-01 induces strong immune responses in phase 2 melanoma trial

You may also like

Crypto prices